Merck's Remigromig Hits Key Endpoint in Phase 2b/3 BRUNELLO Trial

Merck & Co., Inc. (NYSE:MRK) recently announced positive topline results from its Phase 2b/3 BRUNELLO trial, which evaluated remigromig in adults with diabetic macular edema (DME). The trial found that both the 0.5 mg and 0.8 mg doses of remigromig met the primary endpoint by demonstrating non-inferiority to the standard-of-care active control, 0.5 mg ranibizumab, for mean change in best-corrected visual acuity.

While remigromig was generally well-tolerated, higher rates of proliferative diabetic retinopathy, vitreous hemorrhage, and adverse event-related discontinuations were observed in the treatment arms. Full-year one data will be presented at the American Academy of Ophthalmology Annual Meeting on October 10.

The results provide critical proof-of-concept for Merck's novel ophthalmic asset, reinforcing management's strategy to build a high-margin, post-KEYTRUDA growth engine. While safety imbalances and temporary earnings dilution from recent M&A present near-term headwinds, MRK's underlying $16.6 billion quarterly revenue scale and expanding pipeline position it well to capture long-term value if regulatory discussions prove favorable.

Merck's core operational engine remains robust, generating $16.6 billion in Q2 worldwide sales (up 5%). This substantial cash flow allows MRK to seamlessly absorb large strategic acquisitions, such as its $6.8 billion buyout of Terns ($2.31 per share GAAP impact), while simultaneously supporting heavy late-stage clinical development in ophthalmology and immunology without over-leveraging its balance sheet.

Skeptics highlight that while efficacy non-inferiority was achieved, the safety signal creates near-term regulatory and commercial overhangs until full data are dissected. This risk is amplified by Merck's narrowing financial flexibility, following the Terns deal and Cidara transactions, which revised full-year 2026 non-GAAP EPS expectations to $2.66, $2.76 due to $3.62 per share in one-time charges.